Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vivimed Labs's Enterprise Value is ₹4,324.6 Mil.
Vivimed Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil. Therefore, Vivimed Labs's EV-to-OCF for today is .
The historical rank and industry rank for Vivimed Labs's EV-to-OCF or its related term are showing as below:
NSE:VIVIMEDLAB'
s EV-to-OCF Range Over the Past 10 Years
Min: 56.28 Med: 0 Max: 56.28
Current: 56.28
During the past 13 years, the highest EV-to-OCF of Vivimed Labs was 56.28. The lowest was 56.28. And the median was .
NSE:VIVIMEDLAB's EV-to-OCF is ranked worse than 89.09% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.725
vs NSE:VIVIMEDLAB: 56.28
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivimed Labs's PE Ratio (TTM) for today is calculated as:
Vivimed Labs's share price for today is ₹5.08.
Vivimed Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-21.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivimed Labs EV-to-OCF Related Terms
Vivimed Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's EV-to-OCF falls into.
Vivimed Labs's current Enterprise Value is ₹4,324.6 Mil.
Vivimed Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹5.08 is trading 107.3% above its estimated GF Value™ of ₹2.45.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
EV-to-OCF:
GF Value™: ₹2.45 vs. price of ₹5.08 (107.3% above fair value)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
34GF Score
Get the complete analysis for NSE:VIVIMEDLAB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
